Rare diseases
Investigational molecules
Locations
Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus
BulgariaStudy on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment
CzechiaStudy on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis
AustriaStudy on the Effects and Safety of Bulevirtide, Peginterferon Alfa-2a, and Entecavir in Patients with Chronic Hepatitis D
SwedenPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
CzechiaPhase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus
BulgariaStudy of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab
BelgiumA Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment
AustriaStudy on the Effects of Ianalumab in Patients with Sjögren's Syndrome
FranceStudy on Stopping Tenofovir Alafenamide, Tenofovir Disoproxil, and Entecavir in Patients with Chronic Hepatitis B
BelgiumStudy on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis
CzechiaStudy on the Effects of Selgantolimod and NUC Discontinuation in Patients with Chronic Hepatitis B
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
